STOCK TITAN

[6-K/A] Cellectis S.A. Amended Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K/A

Cellectis S.A. filed an amended Form 6-K/A to update its prior submission solely to provide the company’s unaudited interim financial statements in iXBRL format. The amendment covers the three- and six-month periods ended June 30, 2025 and is made in accordance with Rule 405 of Regulation S‑T and the Form 6‑K instructions.

The company states the amendment does not amend, revise, update, or restate other information in the original report. The materials are deemed incorporated by reference into Cellectis’s registration statements on Form F‑3 (Nos. 333‑284302, 333‑288491) and Form S‑8 (including Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Cellectis S.A. ha presentato un Modifica Form 6-K/A per aggiornare la precedente sottomissione esclusivamente fornendo i bilanci intermedi non controllati della società in formato iXBRL. La modifica riguarda i periodi di tre e sei mesi terminati 30 giugno 2025 ed è effettuata in conformità alla Regola 405 del Regulation S‑T e alle istruzioni della Form 6‑K.

La società dichiara che la modifica non modifica, revisiona, aggiorna né riporta altre informazioni nel rapporto originale. I materiali sono ritenuti incorporati per riferimento nelle dichiarazioni di registrazione di Cellectis su Form F‑3 (Nos. 333‑284302, 333‑288491) e la Form S‑8 (inclusi Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Cellectis S.A. presentó una Form 6-K/A modificada para actualizar su envío anterior únicamente para proporcionar los estados financieros intermedios no auditados de la empresa en formato iXBRL. La modificación abarca los periodos de tres y seis meses terminados el 30 de junio de 2025 y se realiza de conformidad con la Regla 405 del Reglamento S‑T y las instrucciones de la Form 6‑K.

La empresa declara que la modificación no modifica, revisa, actualiza ni reexpone otra información en el informe original. Los materiales se consideran incorporados por referencia en las declaraciones de registro de Cellectis en la Form F‑3 (Nos. 333‑284302, 333‑288491) y la Form S‑8 (incluidos los Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Cellectis S.A.는 회사의 미감사 중간 재무제표를 iXBRL 형식으로 제공하기 위하여 이전 제출을 업데이트하는 내용의 Form 6-K/A 개정를 제출했습니다. 이 수정은 2025년 6월 30일 종료된 3개월 및 6개월 기간을 대상으로 하며, Regulation S‑T의 Rule 405 및 Form 6‑K 지침에 따라 이루어졌습니다.

회사는 개정이 원래 보고서의 다른 정보에 대해 수정, 개정, 업데이트 또는 재진술을 수행하지 않는다고 진술합니다. 이 자료들은 Cellectis의 Form F‑3( Nos. 333‑284302, 333‑288491 ) 및 Form S‑8( Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301 )에 대한 등록 신청서에 참조로 수록된 것으로 간주됩니다.

Cellectis S.A. a déposé une Form 6-K/A modifiée pour mettre à jour sa soumission antérieure uniquement pour fournir les états financiers consolidés intermédiaires non audités de la société au format iXBRL. La modification couvre les périodes de trois et six mois se terminant le 30 juin 2025 et est effectuée conformément à la Règle 405 du Regulation S‑T et aux instructions de la Form 6‑K.

La société indique que la modification n’amende ni ne révise, n’actualise ni ne réédite d’autres informations contenues dans le rapport original. Les documents sont réputés incorporés par référence dans les déclarations d’enregistrement de Cellectis sur la Form F‑3 (No. 333‑284302, 333‑288491) et la Form S‑8 (y compris No. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Cellectis S.A. hat ein geändertes Form 6-K/A eingereicht, um seine vorherige Einreichung ausschließlich zu aktualisieren und die un Audited Zwischenfinanzberichte des Unternehmens im Format iXBRL bereitzustellen. Die Änderung deckt die drei- und sechsmonatigen Zeiträume bis zum 30. Juni 2025 ab und erfolgt gemäß Regel 405 der Regulation S‑T und den Anweisungen des Form 6‑K.

Das Unternehmen erklärt, dass die Änderung keine anderen Informationen im ursprünglichen Bericht ändert, überarbeitet, aktualisiert oder neu erklärt. Das Material gilt als durch Bezugnahmen in die Registrierungsunterlagen von Cellectis auf dem Form F‑3 (Nos. 333‑284302, 333‑288491) und dem Form S‑8 (einschließlich Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301) aufgenommen.

Cellectis S.A. قد قدمت Form 6-K/A المعدلة لتحديث تقديمها السابق فقط لتوفير البيانات المالية النصف سنوية غير المدققة للشركة بتنسيق iXBRL. تغطي التعديل فترات الثلاثة والستة أشهر المنتهية في 30 يونيو 2025 ويتم ذلك وفق القاعدة 405 من لوائح S‑T ونماذج 6‑K.

وتفيد الشركة بأن التعديل لا يعدل ولا يراجع ولا يحدث أو يعيد صياغة معلومات أخرى في التقرير الأصلي. materials تعتبر مدرجة بالإشارة ضمن أنشطة التسجيل لـ Form F‑3 (الأرقام 333‑284302, 333‑288491) و Form S‑8 (بما في ذلك الأرقام 333‑204205، 333‑214884، 333‑222482، 333‑227717، 333‑258514، 333‑267760، 333‑273777، 333‑284301).

Cellectis S.A. 已提交经修订的 Form 6-K/A,仅为更新先前提交以提供公司未经审计的中期财务报表,格式为 iXBRL。该修订涵盖截至 2025年6月30日 的三个月和六个月期间,并符合 Regulation S‑T 的 Rule 405 与 Form 6‑K 的说明。

公司表示,该修订不会修改、修订、更新或重新陈述原始报告中的其他信息。材料被视为通过参照并入 Cellectis 的注册声明,适用于 Form F‑3(编号 333‑284302, 333‑288491)和 Form S‑8(包括编号 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301)。

Positive
  • None.
Negative
  • None.

Cellectis S.A. ha presentato un Modifica Form 6-K/A per aggiornare la precedente sottomissione esclusivamente fornendo i bilanci intermedi non controllati della società in formato iXBRL. La modifica riguarda i periodi di tre e sei mesi terminati 30 giugno 2025 ed è effettuata in conformità alla Regola 405 del Regulation S‑T e alle istruzioni della Form 6‑K.

La società dichiara che la modifica non modifica, revisiona, aggiorna né riporta altre informazioni nel rapporto originale. I materiali sono ritenuti incorporati per riferimento nelle dichiarazioni di registrazione di Cellectis su Form F‑3 (Nos. 333‑284302, 333‑288491) e la Form S‑8 (inclusi Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Cellectis S.A. presentó una Form 6-K/A modificada para actualizar su envío anterior únicamente para proporcionar los estados financieros intermedios no auditados de la empresa en formato iXBRL. La modificación abarca los periodos de tres y seis meses terminados el 30 de junio de 2025 y se realiza de conformidad con la Regla 405 del Reglamento S‑T y las instrucciones de la Form 6‑K.

La empresa declara que la modificación no modifica, revisa, actualiza ni reexpone otra información en el informe original. Los materiales se consideran incorporados por referencia en las declaraciones de registro de Cellectis en la Form F‑3 (Nos. 333‑284302, 333‑288491) y la Form S‑8 (incluidos los Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Cellectis S.A.는 회사의 미감사 중간 재무제표를 iXBRL 형식으로 제공하기 위하여 이전 제출을 업데이트하는 내용의 Form 6-K/A 개정를 제출했습니다. 이 수정은 2025년 6월 30일 종료된 3개월 및 6개월 기간을 대상으로 하며, Regulation S‑T의 Rule 405 및 Form 6‑K 지침에 따라 이루어졌습니다.

회사는 개정이 원래 보고서의 다른 정보에 대해 수정, 개정, 업데이트 또는 재진술을 수행하지 않는다고 진술합니다. 이 자료들은 Cellectis의 Form F‑3( Nos. 333‑284302, 333‑288491 ) 및 Form S‑8( Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301 )에 대한 등록 신청서에 참조로 수록된 것으로 간주됩니다.

Cellectis S.A. a déposé une Form 6-K/A modifiée pour mettre à jour sa soumission antérieure uniquement pour fournir les états financiers consolidés intermédiaires non audités de la société au format iXBRL. La modification couvre les périodes de trois et six mois se terminant le 30 juin 2025 et est effectuée conformément à la Règle 405 du Regulation S‑T et aux instructions de la Form 6‑K.

La société indique que la modification n’amende ni ne révise, n’actualise ni ne réédite d’autres informations contenues dans le rapport original. Les documents sont réputés incorporés par référence dans les déclarations d’enregistrement de Cellectis sur la Form F‑3 (No. 333‑284302, 333‑288491) et la Form S‑8 (y compris No. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301).

Cellectis S.A. hat ein geändertes Form 6-K/A eingereicht, um seine vorherige Einreichung ausschließlich zu aktualisieren und die un Audited Zwischenfinanzberichte des Unternehmens im Format iXBRL bereitzustellen. Die Änderung deckt die drei- und sechsmonatigen Zeiträume bis zum 30. Juni 2025 ab und erfolgt gemäß Regel 405 der Regulation S‑T und den Anweisungen des Form 6‑K.

Das Unternehmen erklärt, dass die Änderung keine anderen Informationen im ursprünglichen Bericht ändert, überarbeitet, aktualisiert oder neu erklärt. Das Material gilt als durch Bezugnahmen in die Registrierungsunterlagen von Cellectis auf dem Form F‑3 (Nos. 333‑284302, 333‑288491) und dem Form S‑8 (einschließlich Nos. 333‑204205, 333‑214884, 333‑222482, 333‑227717, 333‑258514, 333‑267760, 333‑273777, 333‑284301) aufgenommen.

Q2--12-310001627281trueJune 30, 2025 0001627281clls:TrancheAWarrantsMemberclls:EuropeanInvestmentBankLoanMember2023-04-170001627281clls:CurrentLeaseDebtsMember2024-12-310001627281ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-12-310001627281clls:NonEmployeeWarrantsMember2023-12-310001627281clls:LicenseAgreementWithServierMember2024-04-012024-06-300001627281ifrs-full:TopOfRangeMember2025-01-012025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2025-04-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:OtherCurrentLiabilities1Member2025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:NotLaterThanOneYearMember2025-06-300001627281clls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281clls:EuropeanInvestmentBankLoanMember2022-12-280001627281clls:ClassAConvertiblePreferredSharesMember2024-05-030001627281clls:BpifranceMemberclls:ResearchTaxCreditFinancingsMember2022-06-152022-06-150001627281clls:FixturesFittingsAndOtherEquipmentMember2024-06-300001627281clls:IncomeLossMember2024-12-310001627281clls:FixturesFittingsAndOtherEquipmentMember2025-06-300001627281clls:StateGuaranteedLoanMember2025-01-012025-06-300001627281ifrs-full:TradeReceivablesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:TrancheAWarrantsMemberclls:ExpectedVolatilityPlusFivePercentMember2025-06-300001627281clls:SubsequentInvestmentAgreementMember2024-05-030001627281clls:TrancheCWarrantsMemberclls:ExpectedVolatilityLessFivePercentMember2025-06-300001627281ifrs-full:BuildingsMember2024-12-310001627281clls:StateGuarantedLoanMember2024-12-310001627281ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2024-06-300001627281clls:NonEmployeeWarrantsMember2024-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:TrancheAWarrantsMember2025-06-300001627281clls:TechnicalEquipmentsMember2025-01-012025-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281clls:FreeSharesMember2025-06-300001627281clls:AstraZenecaMember2025-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:TechnicalEquipmentsMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:TechnicalEquipmentsMember2024-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:CalyxtIncMember2025-01-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMember2024-12-310001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:NonCurrentDerivativeInstrumentsMember2025-06-300001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2024-04-012024-06-300001627281clls:EuropeanInvestmentBankLoanMember2024-12-310001627281clls:TrancheCWarrantsMember2024-12-180001627281clls:TotalNon-CurrentFinancialLiabilitiesAndNon-CurrentLeaseDebtsMember2024-12-310001627281clls:AstraZenecaMemberclls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281clls:EuropeanInvestmentBankWarrantsMember2024-12-310001627281ifrs-full:OrdinarySharesMember2025-06-300001627281clls:LeasedEquipmentMember2025-01-012025-06-300001627281clls:TradePayablesMember2025-06-300001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2024-04-012024-06-3000016272812021-01-012021-12-310001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:EuropeanInvestmentBankLoanMember2025-01-012025-06-300001627281ifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2025-06-300001627281clls:InitialInvestmentAgreementMember2023-11-010001627281clls:FreeSharesMember2023-12-310001627281ifrs-full:SharePremiumMember2025-01-012025-06-300001627281clls:Non-CurrentLeaseLiabilitiesMember2025-06-300001627281clls:CurrentPortionOfState-GuaranteedLoanMember2025-06-300001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:OfficeAndLaboratoryEquipmentMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281clls:TrancheBWarrantsMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:TradePayablesMember2024-12-310001627281clls:EmployeeLitigationAndSeveranceMember2025-06-300001627281clls:AstraZenecaMemberifrs-full:TopOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-012023-11-010001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:CellectisIncMember2025-01-012025-06-300001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281clls:EmployeeLitigationAndSeveranceMember2025-01-012025-06-300001627281clls:ResearchTaxCreditFinancingsMember2025-06-300001627281clls:CarryingAmountAndValueMember2024-12-310001627281clls:CurrentFinancialAssetsMember2024-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2024-06-300001627281ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2024-12-310001627281ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2025-06-300001627281clls:EuropeanInvestmentBankLoanMember2025-06-300001627281clls:EuropeanInvestmentBankLoanTrancheCMember2024-12-182024-12-180001627281clls:BPIRefundableAdvanceAgreementMember2025-01-012025-06-300001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2025-01-012025-06-300001627281ifrs-full:BottomOfRangeMemberclls:StockOption1Member2025-01-012025-06-300001627281clls:LeasedPremisesMemberstpr:NY2025-06-300001627281clls:InitialInvestmentAgreementMember2023-11-012023-11-010001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2025-04-012025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanFiveYearsMember2025-06-300001627281ifrs-full:ConstructionInProgressMember2024-12-310001627281clls:OtherCurrentFinancialLiabilitiesMember2025-01-012025-06-300001627281clls:StockOption1Member2023-12-310001627281clls:CurrentLeaseLiabilitiesMember2024-12-310001627281clls:AstraZenecaMember2025-06-300001627281clls:IncomeLossMember2024-01-012024-06-300001627281clls:AdditionalResearchPlansUnderTheAZJRCAOneMember2024-09-130001627281ifrs-full:PreferenceSharesMember2024-01-012024-06-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001627281clls:ITLicensingAgreementMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:NonCurrentDerivativeInstrumentsMember2024-12-310001627281clls:OtherProvisionForChargesMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:BPIRefundableAdvanceAgreementMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:TopOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-010001627281clls:StockOption1Member2023-01-012023-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:BottomOfRangeMember2024-01-012024-06-300001627281clls:NonEmployeeWarrantsMember2024-12-310001627281clls:AstraZenecaMember2023-11-062023-11-060001627281ifrs-full:BottomOfRangeMemberclls:StockOption1Member2024-01-012024-06-300001627281clls:SubsidiesReceivablesMember2025-06-300001627281clls:StockOption1Member2025-06-232025-06-230001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2024-01-012024-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:OfficeAndLaboratoryEquipmentMember2025-06-300001627281clls:OtherCurrentLiabilities1Memberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:IncomeLossMember2023-12-310001627281clls:EuropeanInvestmentBankLoanTrancheCMember2024-12-180001627281ifrs-full:LaterThanFiveYearsMember2024-12-310001627281clls:SubsequentInvestmentAgreementMember2023-11-140001627281clls:IncomeLossMember2024-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:ExecutiveEmployeesMemberclls:StockOption1Member2025-06-232025-06-230001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:GrossCarryingAmountMember2024-06-300001627281ifrs-full:IssuedCapitalMember2025-06-300001627281clls:TechnicalEquipmentsMember2025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:TradeReceivablesMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:OtherNonCurrentFinancialLiabilitiesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMember2025-06-300001627281ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2024-04-012024-06-300001627281clls:FixturesFittingsAndOtherEquipmentMember2024-01-012024-06-300001627281clls:ExpectedVolatilityLessFivePercentMemberclls:TrancheBWarrantsMember2025-06-300001627281ifrs-full:PreferenceSharesMember2024-06-300001627281clls:CommercialLitigationMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMemberifrs-full:InterestRateMeasurementInputMember2023-10-060001627281clls:CurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281ifrs-full:TradeReceivablesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:ProvisionForTaxLitigationMember2025-01-012025-06-300001627281clls:StateGuaranteedLoanMemberifrs-full:BottomOfRangeMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2023-10-062023-10-060001627281clls:StockOption1Member2024-12-310001627281country:FR2025-01-012025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:TradePayablesMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2025-06-300001627281ifrs-full:OrdinarySharesMember2024-01-012024-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281ifrs-full:BottomOfRangeMemberclls:JointCollaborationAndResearchAgreementMember2023-11-010001627281clls:CellectisBiologicsIncMemberclls:CellectisIncMember2025-01-012025-06-300001627281clls:JointCollaborationAndResearchAgreementMember2023-11-142023-11-140001627281ifrs-full:RetainedEarningsMember2025-01-012025-06-300001627281ifrs-full:BuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281ifrs-full:PreferenceSharesMember2023-11-140001627281clls:EuropeanInvestmentBankWarrantsMember2025-01-012025-06-300001627281clls:CurrentFinancialLiabilitiesMember2024-12-310001627281clls:AstraZenecaMemberifrs-full:OrdinarySharesMember2023-11-060001627281ifrs-full:BuildingsMember2025-01-012025-06-300001627281clls:Non-CurrentLeaseLiabilitiesMember2024-12-310001627281clls:EuropeanInvestmentBankLoanMember2025-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:TechnicalEquipmentsMember2024-06-300001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherCurrentLiabilities1Member2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:OtherNonCurrentFinancialLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2025-01-012025-06-300001627281clls:NonCurrentLeaseDebtsMember2025-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:LandAndBuildingsMember2024-12-310001627281clls:ITLicensingAgreementMemberifrs-full:NotLaterThanOneYearMember2024-12-310001627281clls:ProvisionForTaxLitigationMember2024-12-310001627281clls:AstraZenecaMember2024-05-032024-05-030001627281ifrs-full:LandAndBuildingsMember2025-01-012025-06-300001627281clls:CurrentFinancialAssetsMember2025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:TrancheAWarrantsMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:TradePayablesMember2024-12-310001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:LeasedPremisesMemberstpr:NC2025-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:BPIRefundableAdvanceAgreementMemberclls:BpifranceMember2025-06-300001627281ifrs-full:IssuedCapitalMember2024-12-310001627281ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:RetirementIndemnitiesMember2025-01-012025-06-300001627281ifrs-full:LandAndBuildingsMember2024-01-012024-06-300001627281clls:FreeSharesMember2024-06-300001627281ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2024-06-300001627281ifrs-full:BuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:CashAndCashEquivalentMember2025-06-300001627281clls:AdditionalResearchPlansUnderTheAZJRCATwoMember2024-09-130001627281clls:LeasedEquipmentMemberstpr:NC2025-01-012025-06-300001627281ifrs-full:NotLaterThanOneYearMember2025-06-300001627281ifrs-full:RetainedEarningsMember2025-06-300001627281clls:JointCollaborationAndResearchAgreementMember2024-03-042024-03-040001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:OtherNonCurrentFinancialLiabilitiesMember2025-01-012025-06-300001627281clls:SubsidiesReceivablesMember2024-12-310001627281clls:CurrentPortionOfState-GuaranteedLoanMember2025-01-012025-06-300001627281clls:CurrentLeaseLiabilitiesMember2025-06-300001627281ifrs-full:LandAndBuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:RetirementIndemnitiesMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-060001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanFiveYearsMember2024-12-310001627281clls:AstraZenecaMember2024-12-310001627281clls:ExpectedVolatilityPlusFivePercentMemberclls:TrancheBWarrantsMember2025-06-300001627281clls:AstraZenecaMember2024-12-310001627281ifrs-full:OrdinarySharesMember2023-12-310001627281clls:TrancheCWarrantsMember2024-12-310001627281clls:CurrentPortionOfState-GuaranteedLoanMember2024-12-310001627281clls:StockOption1Member2025-01-012025-06-300001627281clls:TotalCurrentFinancialLiabilitiesAndCurrentLeaseDebtsMember2024-12-310001627281clls:CurrentLeaseLiabilitiesMember2025-01-012025-06-300001627281ifrs-full:GrossCarryingAmountMemberclls:OfficeAndLaboratoryEquipmentMember2024-06-300001627281clls:EuropeanInvestmentBankLoanTrancheBMember2024-01-250001627281ifrs-full:LandAndBuildingsMember2023-12-310001627281clls:OtherCurrentFinancialLiabilitiesMember2025-06-300001627281clls:TrancheAWarrantsMember2023-04-170001627281clls:LicenseAgreementWithServierMember2024-01-012024-06-300001627281clls:CibusSharesMember2025-01-012025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:ResearchAndDevelopmentExpensesMember2024-01-012024-06-300001627281clls:RetirementIndemnitiesMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2024-01-012024-06-300001627281ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2024-06-300001627281clls:TrancheCWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-12-182024-12-180001627281clls:EuropeanInvestmentBankWarrantsMember2025-06-300001627281clls:StateGuarantedLoanMember2025-06-300001627281ifrs-full:IssuedCapitalMemberifrs-full:PreferenceSharesMember2024-01-012024-06-300001627281ifrs-full:Level2OfFairValueHierarchyMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:Non-CurrentPortionOfState-GuaranteedLoanMember2025-01-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:ClassBConvertiblePreferredSharesMember2024-05-030001627281clls:BpifranceMember2025-06-300001627281ifrs-full:TradeReceivablesMember2025-06-300001627281ifrs-full:SharePremiumMember2024-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2024-06-300001627281ifrs-full:GrossCarryingAmountMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:CurrentLeaseDebtsMember2024-12-310001627281clls:CommercialLitigationMember2025-06-300001627281ifrs-full:OrdinarySharesMember2025-01-012025-06-300001627281clls:CalyxtIncMemberclls:VotingAgreementWithCibusMember2025-01-012025-06-300001627281clls:TrancheBWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-01-252024-01-250001627281clls:NonEmployeeWarrantsMember2024-01-012024-12-310001627281ifrs-full:BuildingsMember2025-06-300001627281clls:TechnicalEquipmentsMember2023-12-310001627281clls:TechnicalEquipmentsMember2024-01-012024-06-3000016272812022-01-012022-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-12-310001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:CurrentLeaseDebtsMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:TradePayablesMember2025-06-300001627281clls:ProvisionForTaxLitigationMember2025-06-300001627281clls:PrimeraTherapeuticsIncMember2025-01-012025-06-300001627281clls:SubsequentInvestmentAgreementMember2023-12-310001627281ifrs-full:SharePremiumMember2025-06-300001627281clls:BpifranceMember2025-01-012025-06-300001627281clls:CommercialLitigationMember2024-12-310001627281clls:CarryingAmountAndValueMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:SharePremiumMember2024-01-012024-06-300001627281ifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:NonCurrentFinancialAssetsMember2025-06-300001627281clls:TradePayablesMember2024-12-310001627281ifrs-full:SharePremiumMemberclls:SubsequentInvestmentAgreementMember2024-01-012024-06-300001627281ifrs-full:IssuedCapitalMember2023-12-310001627281clls:StockOption1Member2025-03-132025-03-130001627281clls:TrancheBWarrantsMember2024-01-252024-01-250001627281clls:FreeSharesMember2025-01-012025-06-300001627281country:FR2024-01-012024-06-300001627281ifrs-full:Level1OfFairValueHierarchyMemberclls:TradePayablesMember2024-12-310001627281ifrs-full:RetainedEarningsMember2024-01-012024-06-3000016272812023-12-310001627281ifrs-full:ConstructionInProgressMember2025-06-300001627281clls:AstraZenecaMember2023-11-060001627281clls:BpifranceMemberclls:ResearchTaxCreditFinancingsMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-062024-12-060001627281clls:TotalCurrentFinancialLiabilitiesAndCurrentLeaseDebtsMember2025-01-012025-06-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMemberifrs-full:InterestRateMeasurementInputMember2024-12-060001627281clls:BPIRefundableAdvanceAgreementMember2025-06-300001627281ifrs-full:PreferenceSharesMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:NonCurrentDerivativeInstrumentsMember2025-06-300001627281clls:TotalNon-CurrentFinancialLiabilitiesAndNon-CurrentLeaseDebtsMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2023-06-192023-06-190001627281ifrs-full:RetainedEarningsMember2024-12-310001627281ifrs-full:OrdinarySharesMember2024-12-310001627281clls:StateGuaranteedLoanMemberclls:BpifranceMember2025-01-012025-06-300001627281clls:EmployeeLitigationAndSeveranceMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberclls:TradePayablesMember2024-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2025-06-300001627281clls:StockOption1Member2024-06-300001627281clls:TrancheCWarrantsMember2024-12-182024-12-180001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherNonCurrentFinancialLiabilitiesMember2024-12-310001627281clls:ResearchAndDevelopmentExpensesMember2024-04-012024-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:OfficeAndLaboratoryEquipmentMember2023-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2024-01-012024-06-300001627281ifrs-full:EquityInvestmentsMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2025-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:TrancheBWarrantsMember2024-01-250001627281clls:JointResearchAndCollaborationAgreementInitialInvestmentAgreementSubsequentInvestmentAgreementMember2023-11-140001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281clls:NonEmployeeWarrantsMember2025-06-300001627281clls:FreeSharesMember2024-01-012024-06-300001627281clls:CurrentLeaseDebtsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001627281clls:SubsidiesReceivablesMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281ifrs-full:AccumulatedImpairmentMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2024-01-012024-06-300001627281ifrs-full:GrossCarryingAmountMember2024-06-300001627281clls:TechnicalEquipmentsMember2024-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2025-01-012025-06-300001627281clls:NonCurrentFinancialAssetsMember2024-12-310001627281clls:StateGuaranteedLoanMember2025-06-300001627281clls:ResearchTaxCreditFinancingsMember2024-12-310001627281ifrs-full:SharePremiumMember2024-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-310001627281clls:TrancheAWarrantsMemberclls:ExpectedVolatilityLessFivePercentMember2025-06-300001627281clls:SubsequentInvestmentAgreementMember2024-01-012024-05-030001627281ifrs-full:PreferenceSharesMember2023-11-142023-11-140001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:CashAndCashEquivalentMember2024-12-310001627281ifrs-full:LandAndBuildingsMember2024-06-300001627281ifrs-full:SellingGeneralAndAdministrativeExpenseMember2025-04-012025-06-300001627281clls:TrancheCWarrantsMember2025-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:PreferenceSharesMember2024-12-310001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001627281clls:ITLicensingAgreementMember2024-12-310001627281clls:JointCollaborationAndResearchAgreementMember2024-12-012024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281clls:CashAndCashEquivalentMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001627281clls:IncomeLossMember2025-01-012025-06-300001627281ifrs-full:LaterThanFiveYearsMember2025-06-300001627281ifrs-full:BuildingsMember2023-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:OfficeAndLaboratoryEquipmentMember2024-06-300001627281ifrs-full:TopOfRangeMember2024-01-012024-06-300001627281clls:TrancheCWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-12-180001627281clls:NonCurrentLeaseDebtsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2025-06-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001627281ifrs-full:ConstructionInProgressMember2023-12-310001627281clls:OtherCurrentFinancialLiabilitiesMember2024-12-310001627281clls:CurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281ifrs-full:RetainedEarningsMember2023-12-310001627281clls:TrancheCWarrantsMemberclls:ExpectedVolatilityPlusFivePercentMember2025-06-300001627281clls:FixturesFittingsAndOtherEquipmentMember2024-12-310001627281ifrs-full:BuildingsMember2024-01-012024-06-300001627281ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:BpifranceMember2024-12-310001627281clls:StockOption1Member2024-01-012024-12-310001627281clls:OtherCurrentLiabilities1Member2024-12-310001627281clls:TrancheBWarrantsMember2025-06-300001627281clls:NonCurrentFinancialAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001627281clls:TotalCurrentFinancialLiabilitiesAndCurrentLeaseDebtsMember2025-06-300001627281clls:OtherNonCurrentFinancialLiabilitiesMember2025-06-300001627281ifrs-full:GrossCarryingAmountMember2024-12-310001627281clls:EuropeanInvestmentBankWarrantsMember2024-12-310001627281clls:BPIRefundableAdvanceAgreementMember2023-03-082023-03-080001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281country:FR2025-04-012025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberclls:TechnicalEquipmentsMember2025-06-300001627281ifrs-full:TopOfRangeMemberclls:StockOption1Member2025-01-012025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:OtherCurrentLiabilities1Member2025-06-300001627281ifrs-full:TopOfRangeMemberclls:StockOption1Member2024-01-012024-06-300001627281clls:IncomeLossMember2025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:CalyxtIncMember2017-09-300001627281clls:BPIRefundableAdvanceAgreementMember2023-03-080001627281clls:BPIRefundableAdvanceAgreementMemberclls:BpifranceMember2025-01-012025-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2025-06-300001627281clls:FixturesFittingsAndOtherEquipmentMemberifrs-full:GrossCarryingAmountMember2025-06-300001627281clls:StockOption1Member2025-06-300001627281ifrs-full:ConstructionInProgressMember2025-01-012025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2024-01-012024-06-300001627281clls:ClinicalAndRdAgreementsMember2024-12-310001627281ifrs-full:Level3OfFairValueHierarchyMember2025-06-300001627281clls:BPIRefundableAdvanceAgreementMember2024-12-310001627281clls:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-3100016272812025-01-012025-06-300001627281ifrs-full:NotLaterThanOneYearMember2024-12-310001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanFiveYearsMember2024-12-310001627281ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2025-06-300001627281country:FR2024-04-012024-06-300001627281clls:ExecutiveEmployeesMemberclls:StockOption1Member2025-01-302025-01-300001627281ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001627281clls:ClinicalAndRdAgreementsMemberifrs-full:LaterThanFiveYearsMember2025-06-300001627281ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberclls:CurrentLeaseDebtsMember2025-06-300001627281ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:Non-CurrentLeaseLiabilitiesMember2025-01-012025-06-300001627281ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2024-01-012024-06-3000016272812024-12-310001627281clls:EuropeanInvestmentBankLoanTrancheBMember2024-01-252024-01-250001627281ifrs-full:RetainedEarningsMember2024-06-300001627281clls:Non-CurrentPortionOfState-GuaranteedLoanMember2024-12-310001627281ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2025-06-300001627281clls:ResearchAndDevelopmentExpensesMember2025-04-012025-06-300001627281clls:FixturesFittingsAndOtherEquipmentMember2025-01-012025-06-300001627281clls:NonCurrentDerivativeInstrumentsMemberifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001627281clls:OfficeAndLaboratoryEquipmentMember2024-12-310001627281ifrs-full:ConstructionInProgressMember2024-06-300001627281clls:EuropeanInvestmentBankLoanTrancheAMember2023-04-172023-04-170001627281clls:ClinicalAndRdAgreementsMemberifrs-full:NotLaterThanOneYearMember2024-12-310001627281clls:BpifranceMemberclls:ResearchTaxCreditFinancingsMember2023-06-152023-06-150001627281clls:TotalNon-CurrentFinancialLiabilitiesAndNon-CurrentLeaseDebtsMember2025-01-012025-06-300001627281clls:AstraZenecaIrelandMemberclls:JointCollaborationAndResearchAgreementMember2025-01-012025-06-300001627281ifrs-full:ConstructionInProgressMember2024-01-012024-06-300001627281clls:StockOption1Member2024-01-012024-06-300001627281ifrs-full:LandAndBuildingsMemberifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001627281clls:TrancheBWarrantsMemberclls:EuropeanInvestmentBankLoanMember2024-01-250001627281ifrs-full:TradeReceivablesMember2024-12-310001627281clls:OtherProvisionForChargesMember2025-01-012025-06-300001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-12-310001627281ifrs-full:LandAndBuildingsMember2025-06-300001627281clls:TrancheAWarrantsMember2023-04-172023-04-170001627281clls:CellectisIncMember2024-01-012024-06-300001627281clls:NonCurrentLeaseDebtsMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-12-310001627281clls:TrancheBWarrantsMember2024-01-250001627281clls:FixturesFittingsAndOtherEquipmentMember2023-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2025-06-300001627281clls:OfficeAndLaboratoryEquipmentMember2025-01-012025-06-300001627281ifrs-full:SharePremiumMember2023-12-310001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001627281ifrs-full:AccumulatedImpairmentMember2025-06-300001627281clls:Non-CurrentPortionOfState-GuaranteedLoanMember2025-06-300001627281clls:StateGuaranteedLoanMemberifrs-full:TopOfRangeMember2025-06-300001627281clls:TrancheAWarrantsMember2023-04-170001627281clls:EuropeanInvestmentBankLoanMember2025-04-012025-06-300001627281ifrs-full:Level1OfFairValueHierarchyMember2024-12-3100016272812025-06-3000016272812024-01-012024-06-3000016272812024-06-300001627281clls:CurrentFinancialAssetsMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001627281clls:CurrentFinancialLiabilitiesMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001627281clls:ITLicensingAgreementMemberifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2025-06-300001627281clls:OtherProvisionForChargesMember2024-12-310001627281clls:EuropeanInvestmentBankLoanMember2024-12-310001627281ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2023-12-310001627281clls:ResearchAndDevelopmentExpensesMember2025-01-012025-06-300001627281clls:BPIRefundableAdvanceAgreementMemberifrs-full:InterestRateMeasurementInputMember2023-06-190001627281clls:StateGuaranteedLoanMember2020-07-312020-07-3100016272812024-04-012024-06-300001627281ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2025-06-300001627281clls:CashAndCashEquivalentMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281ifrs-full:Level1OfFairValueHierarchyMemberclls:OtherCurrentLiabilities1Member2024-12-310001627281ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:ConstructionInProgressMember2025-06-300001627281clls:ITLicensingAgreementMemberifrs-full:NotLaterThanOneYearMember2025-06-300001627281clls:SubsidiesReceivablesMemberifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2025-06-300001627281clls:SellingGeneralAndAdministrativeExpenses1Member2025-01-012025-06-300001627281ifrs-full:OrdinarySharesMember2024-06-3000016272812025-04-012025-06-300001627281clls:TrancheCWarrantsMember2024-12-180001627281clls:EuropeanInvestmentBankLoanMember2023-04-172023-04-170001627281clls:NonEmployeeWarrantsMember2025-01-012025-06-300001627281ifrs-full:IssuedCapitalMember2024-06-300001627281ifrs-full:BuildingsMember2024-06-300001627281ifrs-full:BottomOfRangeMember2025-01-012025-06-300001627281clls:NonCurrentLeaseDebtsMember2024-12-310001627281ifrs-full:Level2OfFairValueHierarchyMemberclls:CurrentFinancialAssetsMember2024-12-310001627281clls:TradePayablesMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001627281clls:TechnicalEquipmentsMember2024-12-310001627281ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-12-310001627281clls:NonEmployeeWarrantsMember2024-01-012024-06-300001627281clls:FreeSharesMember2024-12-310001627281clls:ClinicalAndRdAgreementsMember2025-06-300001627281clls:NonEmployeeWarrantsMember2023-01-012023-12-310001627281clls:EuropeanInvestmentBankLoanTrancheAMember2023-04-17iso4217:EURclls:Cellxbrli:pureiso4217:EURxbrli:sharesxbrli:sharesclls:Warrantsclls:Optionsiso4217:USDxbrli:sharesiso4217:USDclls:SegmentUnit

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

Amendment No. 1 to Report on Form 6-K (Film No. 251180769)

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

Date of Report: October 14, 2025

Commission File Number: 001-36891

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry

75013 Paris, France

+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Explanatory Note

This report on Form 6-K/A (this “Amendment”) filed by Cellectis S.A. (the “Company”) amends the Company’s report on Form 6-K, which included the Company’s unaudited Condensed Consolidated Interim Financial Statements as of, and for the three- and six-month periods ended, June 30, 2025 (the “Report”), filed with the U.S. Securities and Exchange Commission on August 4, 2025, solely to provide the financial statements formatted in iXBRL (Inline eXtensible Business Reporting Language) in accordance with Rule 405 of Regulation S-T and paragraph C.(6)(a)(ii) of the General Instructions to Form 6-K. Exhibit 101 includes information in Inline eXtensible Business Reporting Language.


Other than as expressly set forth above, this Amendment does not, and does not purport to, amend, revise, update or restate the information presented in the Report or reflect any events that have occurred after the Report was originally filed.


Cellectis S.A.

 

The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of Cellectis S.A. on Form F-3 (Nos. 333-284302 and 333-288491) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760, 333-273777 and 333-284301), to the extent not superseded by documents or reports subsequently filed.

 

 

 

 


EXHIBIT INDEX

 

Exhibit

 

Title

 

 

 

99.1

 

Cellectis S.A.’s interim report for the six-month period ended June 30, 2025.

 

 

 

101 The following materials from Cellectis S.A.’s Report on Form 6-K formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Financial Position (Unaudited), (ii) the Condensed Consolidated Statements of Operations (Unaudited), (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited), (iv) the Condensed Consolidated Statements of Cash Flow (Unaudited), (v) the Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited), and (vi) the Notes to the Interim Consolidated Financial Statements.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

CELLECTIS S.A.

(Registrant)

 

 

 

October 14, 2025

By:

/s/ André Choulika

 

 

André Choulika

 

 

Chief Executive Officer

 


FAQ

What did Cellectis (CLLS) file?

An amended Form 6-K/A adding iXBRL formatting to its previously filed interim financial statements.

Does this amendment change Cellectis’s results?

No. It does not amend, revise, update, or restate other information from the original report.

Which period do the financial statements cover?

The three- and six-month periods ended June 30, 2025.

What exhibits are included?

Exhibit 99.1 (interim report for six months ended June 30, 2025) and Exhibit 101 (iXBRL-formatted financial statements and notes).

Are these materials incorporated by reference into other registrations?

Yes. They are incorporated by reference into Cellectis’s Form F-3 (Nos. 333-284302, 333-288491) and Form S-8 filings listed.

What is the date of this report?

The Date of Report is October 14, 2025.
Cellectis

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Latest SEC Filings

CLLS Stock Data

453.47M
72.33M
3.85%
18.77%
0.21%
Biotechnology
Healthcare
Link
France
Paris